Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome

Yeny Acosta-Ampudia, Diana M Monsalve, Manuel Rojas, Yhojan Rodríguez, Elizabeth Zapata, Carolina Ramírez-Santana, Juan-Manuel Anaya

Resultado de la investigación: Contribución a una revistaArtículo

Resumen

BACKGROUND: The immunopathological pathways enabling post-COVID syndrome (PCS) development are not entirely known. We underwent a longitudinal analysis of patients with COVID-19 who developed PCS aiming to evaluate the autoimmune and immunological status associated with this condition.

METHODS: Thirty-three patients were included for longitudinal clinical and autoantibody analyses of whom 12 patients were assessed for cytokines and lymphocyte populations. Patients were followed during 7-11 months after acute COVID-19. Autoimmune profile and immunological status were evaluated mainly by enzyme-linked-immunosorbent assays and flow cytometry.

RESULTS: Latent autoimmunity and overt autoimmunity persisted over time. A proinflammatory state was observed in patients with PCS characterized by upregulated IFN-α, TNF-α, G-CSF, IL-17A, IL-6, IL-1β, and IL-13, whereas IP-10 was decreased. In addition, PCS was characterized by increased levels of Th9, CD8+ effector T cells, naive B cells, and CD4+ effector memory T cells. Total levels of IgG S1-SARS-CoV-2 antibodies remained elevated over time.

DISCUSSION: The clinical manifestations of PCS are associated with the persistence of a proinflammatory, and effector phenotype induced by SARS-CoV-2 infection. This long-term persistent immune activation may contribute to the development of latent and overt autoimmunity. Results suggest the need to evaluate the role of immunomodulation in the treatment of PCS.

Idioma originalInglés estadounidense
PublicaciónJournal of Infectious Diseases
DOI
EstadoPublicación electrónica previa a su impresión - ene. 25 2022

Citar esto